Jamjoom Pharma, a leading pharmaceutical company in the Middle East and Africa (MEA), today announced the signing of a Facility Sale and Purchase Agreement with Pfizer Saudi Limited Company to acquire a pharmaceutical manufacturing facility located in King Abdullah Economic City (KAEC), Saudi Arabia.
The facility specializes in the manufacturing and packaging of oral solid dosage (OSD) pharmaceutical products and operates across the full production chain, supported by on-site quality control laboratories. The site represents an important addition to Jamjoom Pharma’s manufacturing network and is expected to enhance its production and operational capabilities.
This step aligns with Jamjoom Pharma’s long-term growth strategy and commitment to advancing local manufacturing capabilities in the Kingdom of Saudi Arabia, supporting national priorities around localization and industrial development. It further enhances regional supply resilience and contributes to expanding access to high-quality, affordable healthcare solutions for patients across the Middle East and Africa.
It also reflects Jamjoom Pharma’s commitment to upholding the highest standards of quality and operational excellence, reinforcing its core value of “Quality Without Compromise”, while building on the strong legacy of Pfizer’s high-quality standards. Moreover, the company is committed to supporting the new workforce stability and fostering a development culture that builds on their established capabilities.
This milestone underscores the company’s vision to be the leading healthcare organization across MEA by 2030, positioning the company for sustainable growth in a rapidly evolving healthcare landscape.
Commenting on the announcement, Tarek Hosni, Chief Executive Officer of Jamjoom Pharma, said:
“This agreement marks an important milestone in our growth journey and reflects our commitment to strengthening our manufacturing capabilities within the Kingdom. We are focused on building a scalable platform that supports sustainable growth while maintaining the highest standards of quality and operational excellence.”
Completion of the transaction remains subject to satisfaction of certain customary conditions precedents, including but not limited to obtaining the necessary regulatory approvals. Jamjoom Pharma will announce any material developments related to the transaction in as required, in accordance with applicable regulatory requirements.
Send us your press releases to pressrelease.zawya@lseg.comDisclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.